Company Information
Industry 制造业
Company Introduction 喜悦伴随着汗水,成功伴随着艰辛,弹指一挥间,辰欣药业已步入了快速发展的轨道。在此,我代表公司全体员工,对关心支持辰欣药业的广大客户、业界同仁和各级领导表示衷心的感谢,并致以崇高的敬意! 一份耕耘,一份收获。经过十几年的辛勤耕耘,辰欣药业从改制成立到逐步成长,从弱小到茁壮,现已被评为高新技术企业、博士后科研工作站、国家认定企业技术中心。 推陈出新,永不止步。我们坚持科技兴企,着力构建企业自主创新体系,将技术创新、质量创新、管理创新、经营理念创新纳入公司的战略规划,已建成了包括“科技进步”、“创新创效”、“合理化建议”在内的科技创新体系,顺利实现了与国际先进水平的接轨,培育出了企业不可复制的核心竞争力。 诚实守信,精诚合作。我们坚信凡事“诚”则“和”,诚信是企业生存与发展之本,只有真正把客户当做朋友,以诚相待,与客户结成事业伙伴,企业才能赢得客户的信任,才能取得双方的共赢。 以人为本,反哺社会。我们履行社会责任,争做良好企业公民。积极参与扶危济困、捐资助学,不断吸纳社会就业,按时足额缴纳税收,解决职工后顾之忧,用行动诠释和践行着“关爱职工,奉献社会”的诺言。 各位同仁、朋友们,辰欣药业发展壮大的每一步、每一程,都离不开社会各界的关心、帮助和支持,各位朋友的信任和扶持是我们执着前行的动力。春天是万物萌发的季节,我们愿与社会各界朋友共同携手,加强合作与交流,共创美好的未来,共同为中国医药事业的健康发展做出贡献!
Main Business 医药产品的研发、生产和销售,以生产化学药品制剂为主。
Legal Representative 杜振新
Top Executives
董事长:杜振新
董事:戈韬,田鹏美,续新兵,卢秀莲,郝留山
独立董事:蔡文春,王唯佳,张自然
Top 5 Shareholder
Shareholder name Nature Holding Date
辰欣科技集团有限公司流通A股26.26%30/09/2024
韩延振流通A股10.06%30/09/2024
四川科伦药业股份有限公司流通A股10.01%30/09/2024
石家庄四药有限公司流通A股6.11%30/09/2024
天津乾鼎企业管理合伙企业(有限合伙)流通A股5.86%30/09/2024
Company Secretary 续新兵
Solicitors 北京市时代九和律师事务所
Auditors 大信会计师事务所(特殊普通合伙)
Tel No 0537-2989906;0537-2985722
Fax No 0537-2215851-002
Website www.cisen-pharma.com
Email cxyy@cisenyy.com
Company Address
Register: 山东省济宁高新区同济科技工业园
Office: 山东省济宁市高新区同济路16号
Listing Date 29/09/2017
Shares Capital
Shares Capital: 452,754,129
Total A Share: 452,754,129
Listed A Share: 452,754,129
Non-tradable A Share: 0
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 1.150
DPS(RMB)* ¥ 0.436
NBV Per Share(RMB)* ¥ 12.649
Market Capitalization(RMB) 6.090B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.